Antennova Concludes Initial Dosing in Phase I ATN-031 Trial

Antennova, a biopharmaceutical firm, has reached a significant milestone with the completion of the initial dosing group in a Phase I clinical trial for ATN-031, a pioneering anti-CD24 monoclonal antibody. The treatment is currently being tested in a multi-center, open-label study known as PERFORM, which is focused on patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). The trial is being led by The University of Texas MD Anderson Cancer Center and includes participation from four major U.S. cancer centers.

In the first cohort, five patients with late-stage cancer have been enrolled, and no dose-limiting toxicities have been observed. Notably, tumor reduction was detected in one patient who had undergone seven prior treatments. Jay Mei, M.D., Ph.D., the Founder and Chairman of Antennova, expressed gratitude for the participants and optimism for the early clinical indications observed in this challenging patient group.

ATN-031 is a novel humanized monoclonal antibody that targets CD24, a protein that cancer cells use to avoid detection and destruction by the immune system. Unlike CD47, another "don't eat me" signal, CD24 has a more limited presence in healthy tissues and is more prevalent in cancerous tissues. The antibody works by blocking the CD24-Siglec-10 interaction, which is a key mechanism of immune evasion in cancer cells. Early research has shown that ATN-031 can bind to CD24 with high specificity and trigger the phagocytosis of cancer cells by macrophages, while also promoting the production of pro-inflammatory cytokines.

Antennova, a subsidiary of Antengene, is dedicated to developing innovative therapies that target the tumor microenvironment to improve the efficacy of existing treatments and overcome resistance to checkpoint inhibitors. The company has four clinical-stage programs, including ATN-031, and has received Orphan Drug Designation from the FDA for two of its therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!